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Wnt/b-catenin signaling plays essential roles in
embryonic development, adult stem cell mainte-
nance, and disease. Screening of a small molecule
compound library with a b-galactosidase fragment
complementation assay measuring b-catenin nu-
clear entry revealed TAK-715 and AMG-548 as
inhibitors of Wnt-3a-stimulated b-catenin signaling.
TAK-715 and AMG-548 are inhibitors of p38
mitogen-activated protein kinase, which has been
suggested to regulate activation of Wnt/b-catenin
signaling. However, two highly selective and equally
potent p38 inhibitors, VX-745 and Scio-469, did not
inhibit Wnt-3a-stimulated b-catenin signaling. Pro-
filing of TAK-715 and AMG-548 against a panel of
over 200 kinases revealed cross-reactivity with
casein kinase Id and 3, which are known activators
of Wnt/b-catenin signaling. Our data demonstrate
that this cross-reactivity accounts for the inhibition
of b-catenin signaling by TAK-715 and AMG-548
and argue against a role of p38 in Wnt/b-catenin
signaling.
INTRODUCTION
Wnt/b-catenin signaling is an evolutionarily conserved intracel-
lular signal transduction pathwaywith important functions during
embryogenesis and adulthood (Logan and Nusse, 2004). It is
initiated by members of the Wnt protein family, a group of glyco-
sylated extracellular ligands that comprises 19 members in
mammals. Wnt proteins (Wnts) bind to a member of the Frizzled
family of seven-transmembrane receptors and a representative
of the low-density lipoprotein receptor-related protein family
(LRP5/6) (Bhanot et al., 1996; Pinson et al., 2000; Wehrli et al.,
2000). These surface proteins initiate an intracellular signaling
cascade that ultimately leads to the cytoplasmic stabilization
of the transcriptional modulator b-catenin. b-Catenin translo-
cates to the nucleus where it interacts with proteins of the
T cell factor/Lymphoid enhancer factor (TCF/LEF) family to influ-
ence the transcription of b-catenin-dependent genes (MolenaarChemistry & Biology 18,et al., 1996). In quiescent cells, the nuclear accumulation of
b-catenin is prevented by the action of a large protein assembly
termed the ‘‘destruction complex.’’ The destruction complex
consists of several scaffolding proteins (e.g., Axin1, Axin2/
Conductin and the protein product of the adenomatous polypo-
sis coli gene [APC]) and the Ser/Thr kinases glycogen synthase
kinase 3 (GSK3a/b) and casein kinase Ia (CKIa). De novo
synthesized b-catenin is recruited to the destruction complex
and then sequentially phosphorylated by CKIa and GSK3
at several N-terminal residues. These phosphate moieties
serve as a cue for proteasomal degradation of b-catenin. As
a result, cytoplasmic b-catenin levels in nonstimulated cells are
typically low.
Aberrations in Wnt/b-catenin signaling activity are associated
with several malignancies, most notably cancer (Barker and
Clevers, 2006; Clevers, 2006). Invariably, these cancers display
elevated levels of nuclear b-catenin and increased expression
of b-catenin-dependent genes. Thus, inhibitors of Wnt/b-catenin
signalingmay have therapeutic utility for treatment of cancer.We
recently described a cell-based screening assay to measure the
cytoplasm-to-nuclear translocation of b-catenin using enzyme
fragment complementation (EFC) (Verkaar et al., 2010). The
b-catenin EFC assay measures the complementation of
a nuclear-resident b-galactosidase deletion mutant (termed
Da-Nuc) with nuclear-translocated b-catenin C-terminally
tagged with a corresponding b-galactosidase fragment (so-
called a-peptide). b-Galactosidase activity generated in this
assay quantitatively reflects nuclear translocation of b-catenin
(Verkaar et al., 2010).
Using the b-catenin EFC assay, we have screened a library of
2300 lowmolecular weight (LMW) synthetic chemicals, including
a panel of kinase inhibitor reference compounds. Our aim was to
identify lead molecules capable of activating or inhibiting Wnt/
b-catenin signaling. A second objective was to couple the effect
of reference compounds in the EFC assay to possible kinase
drug targets within the b-catenin pathway. Here, we describe
assay optimization for automated screening. Furthermore, we
identified inhibition of Wnt/b-catenin signaling as a novel biolog-
ical activity of the anti-inflammatory drugs TAK-715 and AMG-
548, which are inhibitors of p38mitogen-activated protein kinase
(MAPK) and have been in clinical trials for rheumatoid arthritis.
We correlated the inhibition of Wnt/b-catenin signaling by TAK-
715 and AMG-548 to cross-reactivity to casein kinase Id (CKId)
and CKI3, two closely related CKI isoforms that have been shown485–494, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 485
Figure 1. Optimization of Assay Conditions
for the b-Catenin EFC Assay
(A–D) U2OS cells stably overexpressing a nuclear-
resident b-galactosidase enzyme fragment and
a b-catenin fusion protein C-terminally extended
with the complementary b-galactosidase protein
fragment (U2OS-EFC cells) were tested for
b-galactosidase activity after 3 hr of stimulation
withactivators of theb-cateninpathway.Cellswere
plated at several cell densities and incubated with
(A) increasingdosesof recombinantmouseWnt-3a
(rmWnt-3a), (B) 30 mM lithium chloride (LiCl), or
20 mMMG132.Dose-responsiveness of the cells to
rmWnt-3a was determined in the presence of
varying serum (C) or DMSO (D) concentrations.
Data are presented asmean ± SEM. See Figure S1
for results of antagonists, and Table S1 for assay
performance.
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(Peters et al., 1999; Sakanaka et al., 1999; Swiatek et al., 2004).
This side activity may be explored to reposition TAK-715 and
AMG-548 for other indications. Furthermore, our data call for
a reevaluation of studies in which non-selective kinase inhibitors
have been used to implicate p38 in Wnt/b-catenin signaling.
RESULTS
Automated Screening with the b-Catenin EFC Assay
U2OS cells genetically engineered to couple activation of the
Wnt/b-catenin pathway to increases in b-galactosidase comple-
mentation (U2OS-EFC cells) have been described previously
(Verkaar et al., 2010). These cells responded to recombinant
mouse Wnt-3a (rmWnt-3a) with a dose-dependent increase in
b-galactosidase activity (Figure 1A). Several parameters were
varied to optimize the b-catenin EFC assay for automated
screening. First, the number of cells per well was varied, before
stimulating themwith increasing concentrations of rmWnt-3a. As
indicated in Figure 1A, both basal and rmWnt-3a-induced
b-galactosidase activity increased with cell density but there
was no noticeable change in signal-to-noise (S/N) ratio. The
same trend was observed when several amounts of cells were
stimulated with 30 mM lithium chloride (LiCl), which inhibits
GSK3, and 20 mMMG132, which is a proteasomal inhibitor (Fig-
ure 1B). These treatments prevent the degradation of b-catenin
and thereby mimic activation of the Wnt/b-catenin signaling
cascade. We also derived dose-response relationships for486 Chemistry & Biology 18, 485–494, April 22, 2011 ª2011 Elsevier Ltd All rights reservedrmWnt-3a when increasing concentra-
tions of serum and DMSO were added.
We found that at 3%–4% fetal bovine
serum (FBS), the assay signal was slightly
reduced (Figure 1C), and we therefore
conducted all further experiments in
the presence of 2% FBS. We found
that DMSO up to 1% had no effect on
assay response, whereas 2% slightly
decreased assay signal (Figure 1D).
We performed the EFC assay in both
agonistic and antagonistic setup with2311 LMW compounds derived from lead optimization projects
for G protein-coupled receptor (GPCR) or protein kinase targets,
including a set of published kinase inhibitor reference
compounds. The compoundswere tested at 10 mMfinal concen-
tration in 1% DMSO. To control for Wnt/b-catenin pathway acti-
vation, cells were treated with 12 nM rmWnt-3a (500 ng/ml;
EC100). In the antagonistic setup, cells were pretreated
with 10 mM compound for 60 min before addition of 10 nM
rmWnt-3a (420 ng/ml), which corresponded to EC80 pathway
activation. Assay quality was verified by calculating Z’ values
(Zhang et al., 1999).
For the agonistic assay, the average S/N ratio was 4.3 with an
average Z’-value of 0.52. For the antagonistic assay, the average
S/N ratio and Z’-value were 3.4 and 0.57, respectively (see Table
S1 available online). An active was defined as a compound
producing >50% activation/inhibition. Compounds meeting
this criterion were retested to confirm their activity. Three
compounds were found to be active in the initial agonistic screen
and all three could be confirmed upon retesting.
In the antagonistic assay, of the 93 initial actives, 63 were
available for a second experiment. Of these, nineteen
compounds displayed >50% pathway inhibition during the
second test. Representative results for three compounds are
depicted in Figure S1A. The compounds were also able to inhibit
rmWnt-3a-stimulated reporter gene activity in HEK293T
(Figure S1B) and U2OS cells (Figure S1C) stably transfected
with a b-catenin-driven luciferase reporter gene (SuperTOPflash)
(Veeman et al., 2003).
Figure 2. TAK-715 and AMG-548 Inhibit Wnt/b-Catenin Signaling
(A) U2OS-EFC cells were treated with p38 inhibitors at concentrations ranging
from 1 to 10 mM in the presence of 10 nM rmWnt-3a for 3 hr, followed by
measurement of b-galactosidase activity.
(B) U2OS cells stably transfected with SuperTOPflash reporter gene were
treated with p38 inhibitors at the indicated concentrations in the presence of
10 nM rmWnt-3a for 5 hr, and were then tested for luciferase reporter gene
activity.
(C) Selectivity wheel representing the percentage remaining kinase activity of
over 200 purified human kinases tested in 32P incorporation assays in the
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Chemistry & Biology 18,Wnt/b-catenin Signaling Is Not Affected
by p38 MAPK Inhibition
Among the actives in the antagonistic EFC and SuperTOPflash
reporter gene assays were two inhibitors of p38 MAPK:
TAK-715 and AMG-548 (Figures 2A and 2B) (Miwatashi et al.,
2005; Dominguez et al., 2005). Because earlier research has sug-
gested that p38 facilitates Wnt/b-catenin signaling (Bikkavilli
et al., 2008b), we examined the role of p38 in Wnt/b-catenin
signal transduction by testing two other p38 inhibitors, VX-745
and Scio-469 (Dominguez et al., 2005). Figure S2 depicts struc-
tures of all four p38 inhibitors. VX-745 and Scio-469 inhibited p38
enzyme activity in immobilized metal assays for phosphochem-
icals (IMAP) with similar nanomolar potencies as TAK-715 and
AMG-548 (Table S2). However, VX-745 and Scio-469 did not
appreciably inhibit Wnt/b-catenin signaling in the EFC or the
SuperTOPflash reporter gene assay (Figures 2A and 2B), sug-
gesting that the activity of TAK-715 and AMG-548 was due to
cross-reactivity with another kinase. To examine this, the four
p38 inhibitors were screened against a panel of more than
200 kinases at 10 mM in biochemical 32P incorporation assays
(performed at Millipore, Dundee, UK). AMG-548 and TAK-715
inhibited, respectively, 17 and 22 kinases by more than 80%,
whereas VX-745 and Scio-469 only inhibited the a- and b-iso-
forms of p38 by more than 80% (Figure 2C). Five kinases
(CKId, JNK3, MINK, NLK, and YES) were inhibited by both
AMG-548 and TAK-715, but not by VX-745 or Scio-469. Of these
kinases, Nemo-like kinase (NLK) has been associated with
inhibition of Wnt/b-catenin signaling (Ishitani et al., 1999; Ishitani
et al., 2003), whereas CKId, and its closest homolog CKI3,
have been demonstrated to be required for activation of Wnt/
b-catenin signaling (Peters et al., 1999; Sakanaka et al., 1999;
Swiatek et al., 2004). Although both CKI homologs potentially
possess nonoverlapping roles in Wnt/b-catenin signal transduc-
tion, both proteins will on occasion be referred to here as CKId/3
for convenience.
We tested the activity of six different CKI isoforms (i.e., a1, d, 3,
g1, g2, and g3) in the presence of ascending concentrations of
the four p38 inhibitors in Z’-lyte biochemical assays (Rodems
et al., 2002). Although all four inhibited p38a, only TAK-715
and AMG-548 inhibited CKId and CKI3 (Figures 3A–3D). Other
CKI isoforms were not, or only marginally, inhibited by these
compounds (Figures 3A–3D and data not shown).
Wnt-activated CKId/3 induces the phosphorylation of the
cytoplasmic scaffolding protein human Dishevelled-2 (hDvl-2),
which can be visualized by a retarded mobility of this protein
on western blots (Gonzalez-Sancho et al., 2004; Bryja et al.,
2007). As a positive control for inhibition of the pathway, cells
were cotreated with rmWnt-3a and 1 mg/ml humanWnt inhibitory
factor-1 (WIF1), which has been shown to inhibit Wnt/b-catenin
signaling by associating with Wnt proteins (Hsieh et al., 1999).
Treatment with 1 mg/ml WIF1 completely abrogated rmWnt-3a-
induced nuclear translocation of b-catenin in the EFC assay, as
did treatment with 2 mg/ml of the soluble Wnt antagonistpresence of p38 inhibitors at a concentration of 10 mM. Data are presented
as mean ± SEM. Asterisks (*) represent statistically significant differences
(p < 0.05).
See Figure S2 for structures of p38 inhibitors and Table S2 for their activities in
p38 enzyme activity assay.
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Figure 3. TAK-715 and AMG-548 Inhibit Casein Kinase I Isoforms
(A–D) The activity of purified p38, casein kinase Ia (CKIa), CKIg1, CKId, and CKI3 was measured in the presence of ascending concentrations of p38 inhibitor:
TAK-715 (A), AMG-548 (B), Scio-469 (C), and VX-745 (D). Data are presented as mean ± SEM.
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Stimulation of U2OS-EFC cells with 10 nM rmWnt-3a resulted
in a distinct shift of the mobility of hDvl2 to a lower-mobility
form, which was inhibited by cotreatment with WIF1 (Figure 4A).
To demonstrate that the mobility shift of hDvl2 was CKId/3
dependent, we used two published CKI inhibitors, IC261 andFigure 4. Inhibition of CKId/3 Inhibits rmWnt-3a-Induced Phosphorylat
b-Catenin Pathway
(A) U2OS-EFC cells were treated with increasing concentrations of the CKI inhi
rmWnt-3a for 1 hr. Cell lysates were immunoblotted for human Dishevelled-2 (hD
cotreated with 10 nM rmWnt-3a and 1 mg/ml human Wnt inhibitory factor-1 (WIF
(B) U2OS-EFC cells were treated with increasing concentrations of IC261 and D4
b-galactosidase activity. Data are presented as mean ± SEM. See also Figures S
488 Chemistry & Biology 18, 485–494, April 22, 2011 ª2011 ElsevierD4476, which inhibit CKId/3withmicromolar potency (Mashhoon
et al., 2000; Rena et al., 2004). Moreover, IC261 displays bias for
inhibition of CKId and CKI3 over other CKI isoforms (Mashhoon
et al., 2000). Cotreatment of U2OS-EFC cells with 10 nM
rmWnt-3a and ascending concentrations of IC261 or D4476 re-
sulted in a dose-dependent inhibition of the rmWnt-3a-inducedion of Human Dishevelled 2 and Blocks Signaling Through the Wnt/
bitors IC261 (upper panel) and D4476 (lower panel) in the presence of 10 nM
vl2) and b-actin. As a control for Wnt/b-catenin pathway inhibition, cells were
1). See also Figure S3.
476 in the presence of 10 nM rmWnt-3a for 3 hr, followed by measurement of
4 and S5.
Ltd All rights reserved
Figure 5. TAK-715 and AMG-548 Inhibit CKId/3 Activity in U2OS-EFC
Cells
(A) U2OS-EFC cells were treated with vehicle or 10 nM rmWnt-3a in the
presence of 1 mg/ml WIF1, or p38 inhibitors at a concentration of 10 mM.
Subsequently, cellular extracts were analyzed for hDvl2, phospho-Ser1490
low-density lipoprotein receptor-related protein 6 (LRP6) and b-actin by
western blot.
(B) U2OS-EFC cells were stimulated with 10 nM rmWnt-3a in the presence of
increasing concentrations of TAK-715 (upper panel) and AMG-548 (lower
panel) for 1 hr. Cell lysates were probed for hDvl2 and b-actin.
(C) U2OS-EFC cells were cotreated with 10 nM rmWnt-3a and increasing
concentrations of Scio-469 (upper panel) and VX-745 (lower panel) for 1 hr,
followed by western blotting for hDvl2 and b-actin.
See Figure S6 for quantification of peak intensities of low versus high mobility
hDvl2 of blots in Figure 5B and C.
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cations of the peak intensity of phosphorylated versus non-
phosphorylated hDvl2 on these blots. When tested in the EFCChemistry & Biology 18,(Figure 4B) and TOPflash assay (data not shown), IC261 and
D4476 inhibited activation of Wnt/b-catenin signaling with
a potency similar to that observed for the inhibition of hDvl2
phosphorylation. Additionally, we transfected U2OS-EFC cells
with siRNAs targeting p38 or CKId/3 and verified knock-down
of these proteins by western blotting (Figure S5A). We observed
that knock-down of CKId/3, but not p38, inhibited the rmWnt-3a-
dependent mobility shift of hDvl2 (Figure S5A; see Figure S5B for
a quantification of the Dvl2 peak intensity on this blot). These
results confirmed that CKId and CKI3 are responsible for hDvl2
phosphorylation (Bryja et al., 2007). In addition, we demon-
strated that inhibition of CKId and CKI3 can account for the inhi-
bition of Wnt/b-catenin signaling observed in U2OS-EFC cells
treated with TAK-715 or AMG-548.
We subsequently tested the ability of the four p38 inhibitors to
inhibit the Wnt-3a-induced hDvl2 mobility shift in U2OS-EFC
cells. TAK-715 and AMG-548 inhibited the hDvl2 shift at
10 mM, whereas Scio-469 and VX-745 did not (Figure 5A).
Upon Wnt treatment, Ser1490 of LRP6 is phosphorylated by
the sequential activity of GSK3 and CKIg (Tamai et al., 2004;
Davidson et al., 2005). We did not observe any change in LRP6
phosphorylation by TAK-715 or AMG-548 (Figure 5A), indicating
that inhibition of CKIg did not contribute to the inhibitory effect of
these compounds on Wnt/b-catenin signaling. This is consistent
with the inability of both compounds to inhibit CKIg in biochem-
ical assays (Figures 3A and 3B). We subsequently studied the
dose-dependency of the TAK-715- and AMG-548-mediated
inhibition of Wnt-3a-induced hDvl2 phosphorylation. TAK-715
and AMG-548 inhibited the hDvl2 shift at micromolar concentra-
tions (Figure 5B). In contrast, Scio-469 and VX-745 did not inhibit
the Wnt-3a-induced hDvl2 mobility shift at concentrations up to
10 mM (Figure 5C). The peak intensity ratio of nonphosphorylated
versus phosphorylated hDvl2 of these blots is depicted in Fig-
ure S6. Thus, the concentrations of TAK-715 and AMG-548
necessary to inhibit CKId/3 in cells closely approximate those
required to inhibit Wnt/b-catenin signaling in the TOPflash and
EFC assays. This finding, along with the biochemical profile of
TAK-715 and AMG-548, strongly suggests that the effect of
these compounds on Wnt/b-catenin signaling is mediated
through CKId/3 cross-reactivity.
Earlier reports have implicated p38 in Wnt/b-catenin signaling
on the basis of experiments studying the effect of the small mole-
cule p38 inhibitors SB203580 and SB239063 on F9 mouse
teratocarcinoma cells and HEK293 cells (Bikkavilli et al.,
2008a; Bikkavilli et al., 2008b; Cervenka et al., 2011). In line
with these reports, F9 cells transiently transfected with Super-
TOPflash reporter gene construct and subsequently cotreated
with rmWnt-3a and increasing concentrations of SB203580 or
SB239063 displayed a dose-dependent decrease in reporter
gene activity (Figure 6A). Similarly, SB203580 and SB239063
dose-dependently inhibited b-galactosidase activity in U2OS-
EFC cells induced by rmWnt-3a (Figure 6B). We investigated
whether the inhibition of Wnt/b-catenin signaling in these cells
was due to inhibition of CKId/3. First, we tested SB203580 and
SB239063 in Z’-lyte biochemical assays and observed that
both compounds inhibited CKId/3 with micromolar potency
(Figures S7A and S7B). In addition, treatment of F9 cells with
10 mM SB203580 or SB239063 inhibited the rmWnt-3a-induced
mobility shift of Dvl2 (Figures 6C and 6D). Similarly, HEK293T485–494, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 489
Figure 6. The p38 Inhibitors SB203580 and SB239063 Inhibit Wnt/b-Catenin Signaling in F9 Mouse Teratocarcinoma Cells and U2OS-EFC
Cells Through Inhibition of CKId/3
(A) F9 cells were transiently transfected with SuperTOPflash reporter gene construct. Forty-eight hours after transfection, cells were stimulated with 10 nM
rmWnt-3a and increasing concentrations of SB203580, SB239063, Scio-469, or VX-745 for 5 hr before measurement of luciferase activity.
(B) U2OS-EFC cells were treatedwith 10 nM rmWnt-3a in the presence of increasing concentrations of SB203580, SB239063, Scio-469, or VX-745 for 3 hr prior to
measurement of b-galactosidase activity.
(C) F9 cells were stimulated with 10 nM rmWnt-3a in the presence or absence of 1 mg/ml WIF1 or 10 mM p38 inhibitor as indicated in the figure for 1 hr. Lysates
were probed for Dvl2 and b-actin.
(D) A quantification of the ratio between phosphorylated and nonphosphorylated Dvl2 derived from the blot in (C). Data are presented asmean ± SEM. Asterisks (*)
represent statistically significant differences (p < 0.05).
See also Figures S7 and S8.
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and S8D) treated with SB203580 or SB239063 also displayed
impaired mobility of hDvl2 in response to rmWnt-3a. Thus,
CKId/3 cross-reactivity is a common trait for p38 inhibitors that
may have confounded the interpretation of previously reported
results.
p38 Is Not Activated upon Treatment with Wnt-3a
Our data argue against a role for p38 in activation of Wnt/b-cat-
enin signaling, but they do not exclude the possibility that p38 is
activated upon Wnt treatment. To directly test this, U2OS-EFC
cells were treated with Wnt-3a for 15 and 60 min before the cells
were lysed, and lysates were analyzed for phosphorylated p38.
As a positive control for p38 activation, cells were incubated
with the protein kinase C activator phorbol 12-myristate
13-acetate (PMA). We also assessed the phosphorylation status
of extracellular stimulus-regulated kinase 1/2 (ERK1/2) and Akt/
protein kinase B. ERK1/2 is activated by PMA (Graves et al.,490 Chemistry & Biology 18, 485–494, April 22, 2011 ª2011 Elsevier1995), whereas activation of Akt can be accomplished by treat-
ment with insulin (Cross et al., 1995).
Treatment with 10 mM PMA caused a marked increase in
phosphorylated p38 (Thr180/Tyr182) and ERK1/2 (Thr202/
Tyr204) (Figure 7). However, 10 nM rmWnt-3a had no effect on
phosphorylation of these kinases (Figure 7). Phosphorylation of
Akt/PKB (Ser473) was induced by 100 ng/ml insulin but not by
treatment with rmWnt-3a (Figure 7). In contrast, rmWnt-3a acti-
vated phosphorylation of LRP6, whereas other treatments did
not (Figure 7). These data demonstrate that p38 is not activated
during Wnt/b-catenin signaling in U2OS-EFC cells. We also did
not detect phosphorylation of GSK3b at Ser9 after Wnt-3a treat-
ment (Figure 7), which has been suggested to mediate the effect
of p38 onWnt/b-catenin signaling (Bikkavilli et al., 2008b). Phos-
phorylation of GSK3b was readily observed following treatment
with insulin and PMA (Figure 7), as has been reported previously
(Cross et al., 1995). We extended our analysis by examining the
phosphorylation of p38 and ERK1/2 in F9 cells and HEK293TLtd All rights reserved
Figure 7. p38 Is Not Activated by rmWnt-3a Treatment in U2OS-EFC
Cells
U2OS-EFC cells were treated with vehicle (Veh), 10 nM rmWnt-3a (Wnt),
100 ng/ml insulin (Ins), or 10 mM phorbol 12-myristate 13-acetate (PMA) for 15
or 60 min. Lysates were analyzed for phospho-Thr180/Tyr182 p38, phospho-
Thr202/Tyr204 extracellular–regulated kinase 1/2 (ERK1/2), phospho-Ser473
Akt/protein kinase B, phospho-Ser9 glycogen synthase kinase 3b (GSK3b),
and phospho-Ser1490 LRP6 by western blotting. See also Figure S9.
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cells, F9 cells (Figure S9A) and HEK293T cells (Figure S9B) did
not activate p38 and ERK1/2 following rmWnt-3a-treatment,
whereas phosphorylation at Ser1490 of LRP6 and the Wnt-3a-
induced mobility shift of Dvl2 were readily observed.
We conclude that inhibition of Wnt/b-catenin signaling by
TAK-715 and AMG-548 is not due to their primary activity on
p38, but most likely due to cross-reactivity with CKId/3. Further-
more, we have found no evidence of p38 activation following
Wnt/b-catenin signaling in F9, HEK293T, and U2OS cells.
DISCUSSION
High-throughput screening revealed inhibition of Wnt/b-catenin
signaling as a side activity of the p38 inhibitors TAK-715 and
AMG-548. Two other equally potent, but more selective p38
inhibitors, VX-745 and Scio-469, did not inhibit Wnt/b-catenin
signaling. We could attribute the activity of TAK-715 and AMG-
548 to cross-reactivity with CKId/3. The ATP-binding pockets
of p38 and CKId appear to be structurally similar, because
CKId/3 cross-activity is commonly observed for p38 inhibitors
(Godl et al., 2003; Hasegawa and Cahill, 2004; Bain et al.,
2007). Reciprocally, several CKI inhibitors cross-react with p38
(Bain et al., 2007). The implications of this are two-fold.
First, the inhibitory effect on Wnt/b-catenin signaling and their
cross-reactivity with CKId may be explored in drug discoveryChemistry & Biology 18,with the final aim to reposition TAK-715 and AMG-548 for other
indications, such as cancer (Barker and Clevers, 2006; Clevers,
2006). For instance, mutations in CKI3 have recently been linked
to breast cancer, and the proliferation of several breast cancer
cell lines has been shown to be CKI3 dependent (Kim et al.,
2010; Foldynova-Trantirkova et al., 2010). In addition, CKId and
CKI3 are key regulators of the mammalian circadian clock, and
inhibitors of these kinases may potentially alleviate misalignment
of the internal clock, as experienced during jet lag, depression,
and seasonal affective disorder (Barnard and Nolan, 2008),
provided these compounds pass the blood-brain barrier.
SB239063 has been shown to display efficacy in reducing
ischemic cerebral damage (Barone et al., 2001a; Barone et al.,
2001b), which implies that it enters the brain, but whether TAK-
715 and AMG-548 cross the blood-brain barrier has not been
reported.
Second, our data argue against a role of p38 in Wnt/b-catenin
signaling, in apparent contrast to suggestions by others (Caver-
zasio and Manen, 2007; Thornton et al., 2008; Bikkavilli et al.,
2008b). These discrepancies may be explained by the fact that
in earlier studies, activation of p38 in F9 cells was assessed by
determining the phosphorylation of the p38 substrate activating
transcription factor 2 (ATF2) (Bikkavilli et al., 2008b), whereas we
determined p38 activity directly. ATF2 phosphorylation may
occur upon activation of other signaling pathways, such as
c-jun N-terminal kinase (JNK) (Gupta et al., 1995). Bikkavilli
and colleagues reported that wild-type F9 cells did not activate
JNK signaling (Bikkavilli et al., 2008a). However, they employed
F9 cells stably expressing rat Frizzled-1 for their analysis of p38
signaling (Bikkavilli et al., 2008b), and these cells were previously
reported to activate JNK signaling upon Wnt-3a-treatment (Bik-
kavilli et al., 2008a). Thus, activation of JNK, and not p38, may
account for the ATF2 phosphorylation observed in these
experiments.
p38 was suggested to activate Wnt/b-catenin signaling by
inactivation of GSK3b through phosphorylation at Ser9 in F9
(Bikkavilli et al., 2008b) or Thr390 in HEK293 cells and mouse
thymocytes (Thornton et al., 2008). We did not observe phos-
phorylation of GSK3b at Ser9 or Thr390 in U2OS-EFC cells stim-
ulated with Wnt-3a for 15 or 60 min (Figure 7 and data not
shown), in line with earlier reports (Ding et al., 2000; McManus
et al., 2005). We also did not observe activation of ERK1/2 in
U2OS-EFC cells treated with Wnt-3a, which has been reported
to occur in several cell lines after stimulation with Wnt-3a-condi-
tioned medium or transfection of Wnt-3a-coding vector (Civenni
et al., 2003; Almeida et al., 2005; Yun et al., 2005; Caverzasio
and Manen, 2007; Kim and Choi, 2007). It should be noted that
conditioned media can be heterogeneous in composition and
the ERK1/2 phosphorylation observed by others may be due to
the presence of factors other than Wnt-3a present within the
conditioned medium.
SIGNIFICANCE
Overly active Wnt/b-catenin signaling plays a critical role in
many diseases (Barker and Clevers, 2006; Clevers, 2006).
We found that the unanticipated cross-reactivity of the
p38-inhibiting drugs TAK-715 and AMG-548 accounted for
their ability to inhibit the Wnt/b-catenin pathway. TAK-715485–494, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 491
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b-catenin- and CKId/3-dependent indications. TAK-715
and AMG-548 have been evaluated in clinical trials for
rheumatoid arthritis and have been shown to possess
good pharmacokinetic properties (Miwatashi et al., 2005;
Dominguez et al., 2005). This makes TAK-715 and AMG-548
attractive starting points for chemical optimization.
Wnt/b-catenin signaling has proved difficult to target with
small molecule compounds because of the unavailability of
suitable drugable targets (Garber, 2009). Combining high-
throughput screening of small molecule kinase inhibitors
with biochemical profiling of kinase targets, as described
here, could serve to quickly select a target set that can
then be assessed using siRNA or gene knock-out
approaches for target validation. To our knowledge, this
chemo-genomics approach has not been previously
explored for drug discovery on Wnt/b-catenin signaling.
Finally, our results should create awareness of the limita-
tions of using small molecule ATP-competitive kinase inhib-
itors as tools for pathway analysis. The data presented here
form an example of how cross-reactivities can potentially
lead to misinterpretation of results unless verified by using
multiple kinase inhibitors from structurally distinct classes
and by correlating the cellular potency of the inhibitor to
the observed effect.EXPERIMENTAL PROCEDURES
Cell Lines
HEK293T, U2OS, and F9 cells were obtained from the American Type Culture
Collection (ATCC) and cultured in DMEM F12 containing 10% fetal bovine
serum (FBS; Cambrex, Verviers, Belgium), 100 U/ml penicillin, and 100 mg/ml
streptomycin (Invitrogen, Breda, The Netherlands). The generation of U2OS-
EFC cells has been described elsewhere (Verkaar et al., 2010). This cell line
was cultured in DMEM F12 supplemented with 10% FBS, 100 U/ml penicillin,
100 mg/ml streptomycin, 150 mg/ml hygromycin, and 500 mg/ml geneticin
(Invitrogen).
LMW Compounds and Recombinant Proteins
Synthetic organic LMW compounds were selected from the Merck Research
Laboratories compound collection (Oss, The Netherlands) according to
previously determined activity on various G protein–coupled receptor
(GPCR) or protein kinase targets. IC261 was purchased from Calbiochem
(Gibbstown, NJ). D4476 and SB239063 were obtained from Tocris Cookson
Inc. (St. Louis, MO). Recombinant mouse Wnt-3a (rmWnt-3a), recombinant
human Wnt inhibitory factor-1 (WIF1), and recombinant human Dickkopf-1
(rhDkk-1) were purchased from R&D Systems (Abingdon, UK).
b-Galactosidase Fragment Complementation Assays
The agonistic b-catenin EFC assay has been described previously (Verkaar
et al., 2010). For antagonistic testing, cells were seeded in 384-well Cultur-
Plates (PerkinElmer, Boston, Massachusetts) with 0.5 3 104 U2OS-EFC cells
in 22.5 ml DMEM F12 containing 2% FBS, 100 U/ml penicillin, and 100 mg/ml
streptomycin (assay medium). After overnight incubation at 37C in a humidi-
fied incubator (5% CO2, 95% humidity), 2.5 ml compound or DMSO control in
assay medium was added to the cells and the plate was returned to the incu-
bator for 1 hr. Cells were then stimulated with 2.5 ml of rmWnt-3a in assay
medium (final concentration of 420 ng/ml [10 nM]) and returned to the incu-
bator for 3 hr. Cells were disrupted using 12.5 ml of substrate-containing lysis
buffer from the PathHunter Detection Kit in the formulation specified by the
supplier (DiscoveRx). Plates were incubated in the dark for 1 hr at room
temperature before measurement of b-galactosidase activity on an Envision
multilabel plate reader (PerkinElmer).492 Chemistry & Biology 18, 485–494, April 22, 2011 ª2011 ElsevierSuperTOPflash Reporter Gene Assays
Transient transfection of DNA was described previously (Verkaar et al., 2009).
Transfection of siRNA was described elsewhere (Verkaar et al., 2010). siRNAs
targeting p38, CKId, and CKI3 and nontargeting control siRNAs were
purchased from Thermo Fischer Scientific (Waltham, Massachusetts). For
stable transfections, HEK293T and U2OS cells were transfected with pTA-
superTOPflash and pIRESpuro2 (Clontech; Mountain View, CA) at a 10:1molar
ratio using Lipofectamine 2000 (Invitrogen). Forty-eight hours after transfec-
tion, growth medium was replaced by medium containing 2 mg/ml puromycin
(Calbiochem, San Diego, California) and cells were dispensed into 96-well
plates for single cell clone selection by means of limited dilution. Single-cell
clones were seeded in 384-well CulturPlates (PerkinElmer) at 104 (HEK293T)
or 0.5 3 104 (U2OS) cells/well in 10 ml DMEM F12 supplemented with 1 mg/ml
insulin (Sigma-Aldrich, Steinheim, Germany), 5 mg/ml apo-transferrin (Sigma-
Aldrich), 100 U/ml penicillin, and 100 mg/ml streptomycin (IT-medium). After
overnight incubation, cells were stimulated with 5 ml of compound or DMSO
in IT-medium for 1 hr, followedby addition of 5 ml of rmWnt-3a or vehicle control
in IT-medium. Plateswere incubated at 37C for 5 hr and then allowed to cool to
room temperature before addition of 15 ml of SteadyLite reagent (PerkinElmer).
After a 30 min incubation at room temperature in the dark, chemiluminescent
activity was measured on an Envision multilabel plate reader.
Western Blotting
Isolation of cell lysates, followed bywestern blotting, was described previously
(Verkaar et al., 2010). The following antibodies were used at the indicated
dilutions: mouse anti-b-actin, 1:5000; mouse anti-casein kinase Id, 1:1000;
and mouse anti-casein kinase I3, 1:1000 (Abcam, Cambridge, UK); rabbit
anti-dishevelled-2, 1:2000; rabbit-anti-Akt, 1:1000; rabbit anti-GSK3b,
1:1000; rabbit anti-phospho-Ser473 Akt, 1:1000; rabbit anti-phospho-Ser9
GSK3b, 1:1000; rabbit anti-phospho(Thr202/Tyr204)-ERK1/2, 1:1000; rabbit
anti-LRP6, 1:1000; and rabbit anti-phospho-Ser1490 LRP6, 1:1000 (Cell
Signaling Technology, Danvers, Massachusetts); mouse-anti-p38, 1:1000;
rabbit anti-phospho(Thr180/Tyr182)-p38 and rabbit anti-ERK1/2 (Invitrogen),
anti-mouse-HRP conjugate, 1:2000; and anti-rabbit-HRP conjugate, 1:2000
(Promega, Leiden, The Netherlands).
Kinase Assays
Immobilizedmetal assays for phosphochemicals (IMAP) for p38 kinase activity
were performed as described previously (Loomans et al., 2003). Assays for
casein kinase isoforms (Rodems et al., 2002) were performed at Invitrogen
(Paisley, UK).Whole kinome profiling was performed atMillipore (Dundee, UK).
Data Analysis
Concentrations of rmWnt-3a were calculated from the expected molecular
mass of recombinant Wnt-3a (41 kDa). Data were analyzed using Graphpad
Prism 4.0 software. All data are represented as averages ± standard error of
the mean (SEM). Statistical significance of observed differences was deter-
mined using Student’s t test and indicated in the figures with asterisks (*);
p < 0.05 was regarded as statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes nine figures and two tables and can be
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